
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
A Boston-based biotechnology company has dosed the first patient in a Phase 1 clinical trial of a drug designed to reverse age-related vision loss by resetting the epigenetic code of damaged cells. The therapy, called ER-100, is the first cellular rejuvenation treatment using epigenetic reprogramming to reach human trials. Life Biosciences announced the milestone Monday. […]









